Last reviewed · How we verify
Air Liquide Santé International — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Kalinox 170 bar | Kalinox 170 bar | marketed | ||||
| sévoflurane | sévoflurane | marketed | ||||
| Mix of 50% oxygen and 50% nitrogen | Mix of 50% oxygen and 50% nitrogen | marketed | Medical gas | Respiratory/Anesthesia | ||
| EMONO | EMONO | phase 3 | Therapeutic gas | Critical Care / Pulmonary | ||
| Air/Oxygen | Air/Oxygen | phase 3 | Medical gas | Respiratory / Critical Care |
Therapeutic area mix
- Critical Care / Pulmonary · 1
- Respiratory / Critical Care · 1
- Respiratory/Anesthesia · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Central Denmark Region · 1 shared drug class
- University of South Florida · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Air Liquide Santé International:
- Air Liquide Santé International pipeline updates — RSS
- Air Liquide Santé International pipeline updates — Atom
- Air Liquide Santé International pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Air Liquide Santé International — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/air-liquide-sant-international. Accessed 2026-05-17.